The cardiovascular safety of incretin-based therapies: a review of the evidence. - Wikidata - awgldk - TriplyDB

The cardiovascular safety of incretin-based therapies: a review of the evidence.

The cardiovascular safety of incretin-based therapies: a review of the evidence.

http://www.wikidata.org/entity/Q38134902

about

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.Incretin-based therapies in prediabetes: Current evidence and future perspectives Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production.Tolerability and safety of the new anti-obesity medications.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Implications of incretin-based therapies on cardiovascular disease.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.Combination therapy when metformin is not an option for type 2 diabetes.Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.Controlled release of biologics for the treatment of type 2 diabetes.Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps.Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms.Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation.

P2860

Q31043538-E69D04E2-4B6C-40FD-8242-4024D85DAF9B Q34699191-68CFE0D7-EF44-4FA5-818D-AA0FB77117E9 Q35784692-18583DC4-DC5D-45AA-8BDE-3D801DAA9B30 Q36758314-44D0291F-9123-4FA4-B540-0342107FF185 Q37686091-65A0C65A-D44B-4C9A-9A41-5AC5DE052898 Q38237336-EA477E27-3DC0-47C8-9CD5-3C92278E1272 Q38261236-8823FC8D-7FC6-415F-86D2-E513F815BDB3 Q38264374-C82F508F-1EF8-4CF4-8EB3-4137B00641DF Q38371242-37CDE515-BF8D-42FC-99E0-B50EEECCD5AA Q38377267-C4935039-76CC-4415-ABF3-B986CA99998C Q38597109-01E4B2DB-E472-4206-B0BD-866CE025BB8F Q38665753-68C4B6ED-91CB-4625-9F72-21C62D1578AF Q39027188-0BC14335-61CC-4F00-9F97-FA8DA2635914 Q44633782-2ABF2F99-12B3-4B4D-8DF4-A5A477BE296B Q48277313-5701FB07-1394-4B23-AB28-DA2BA6309421 Q49833824-CD78058F-B3A6-4978-AFAF-B80C660206A5 Q54311139-EA20DB91-6555-4486-A3AE-16659CA5A1B3

P2860

The cardiovascular safety of incretin-based therapies: a review of the evidence.

http://www.wikidata.org/entity/Q38134902

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The cardiovascular safety of incretin-based therapies: a review of the evidence.

@en

type

label

The cardiovascular safety of incretin-based therapies: a review of the evidence.

@en

prefLabel

The cardiovascular safety of incretin-based therapies: a review of the evidence.

@en

P1433

Q38134902-B56F1E55-7996-450A-B230-820740837F88

P1476

Q38134902-E133EE03-F305-41F4-9901-3A2174B143B5

P2093

Q38134902-72058CC3-0AC7-4A86-A91A-53185BE157BB

P275

Q38134902-D19F8573-A207-4C54-BBD3-D3165DFB3651

P2860

Q38134902-024FCBDD-E586-4A01-A2BA-C756B2768526

Q38134902-027B202F-EA39-4A58-A7C0-9E2E9F5E2DEB

Q38134902-05E7FC05-872A-40E9-AF00-1E8B58C23FF0

Q38134902-05FA26FB-D0B1-4B04-AA6A-DDED486ADA5B

Q38134902-08BB282E-93F1-4E6F-911B-E6225E1A80A1

Q38134902-0B90D92D-B9FC-44DD-A1C2-5EC1523857B3

Q38134902-110F55DF-92B6-402D-951F-FBDB0F0325CB

Q38134902-1349ACE9-0715-492C-983B-EFD343CB2BCC

Q38134902-181739F3-2E85-4334-B94D-A7880368C1A2

Q38134902-19099C66-8377-43BD-9311-0D4EBAFC5AC9

P2888

Q38134902-F1A3EC45-1F9C-4FDC-9A58-B1B7CBF52D7B

P304

Q38134902-EE7AAC0B-B132-4825-B32A-1C83D23A1D75

P31

Q38134902-24C4BF3D-0554-44B6-B164-61CC6BE43C21

Q38134902-895C8BD1-7BF9-4519-9825-4DBF54D84529

P356

Q38134902-DDB6C898-795B-46CA-93FC-FF6E2E268847

P407

Q38134902-9938A66D-CBDC-4354-A8A5-A9703A815189

P478

Q38134902-877CE185-59CC-42D3-B0C6-358C51DC84D9

P5008

Q38134902-76365183-CCF9-43F2-9FE0-9D1EEECB12A9

P577

Q38134902-A7FEAE41-1D44-478D-97A7-780225517694

P5875

Q38134902-F201CB97-3B52-46E1-92C9-1A5D6B0D662D

P6179

Q38134902-08D7303B-B97A-4CEB-911C-A53A9614424B

P698

Q38134902-1CFA514D-635B-465D-B1C9-B344D06E3300

P921

Q38134902-2452B365-14E9-4B9E-8ADD-9D6FB5A7D37E

Q38134902-40B1721D-2BC5-473C-B846-3CE2ED9C6740

Q38134902-8880A071-D072-42C7-BB03-D2BD16CDA940

Q38134902-B047D92F-426F-4AED-AC76-5B88A688ABED

P932

Q38134902-C23BA9AC-0A79-4F49-8CBF-CCCDF906C941

P356

1475-2840-12-130

P1433

Cardiovascular Diabetology

P1476

The cardiovascular safety of incretin-based therapies: a review of the evidence.

@en

P2093

John R Petrie

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Biology of incretins: GLP-1 and GIP

P2888

1475-2840-12-130

P304

130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2840-12-130

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256467136

http://www.w3.org/2001/XMLSchema#string

P6179

1018780038

http://www.w3.org/2001/XMLSchema#string

P698

24011363

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

cardiovascular disease

maturity-onset diabetes of the young

P932

3847044

http://www.w3.org/2001/XMLSchema#string